CytoSorbents preliminary FY2022 revenue $34.7M; core product sales constant currency down 4.6%

Cytosorbents Corp

2022-FY EPS reported -$0.75 revenue$34,688,809

Preliminary FY2022 total revenue $34.7M vs $43.2M in 2021; product sales $29.4M (Q4 $7.6M, +18% sequentially).
Core non-COVID product sales $29.1M; constant currency ~$32.2M, down 4.6% from 2021.
Q4 2022 core product sales constant currency $8.5M (+6% YoY); cumulative CytoSorb treatments >195,000 (+20% YoY).
Cash $23.8M at year end; $5M Bridge Bank term loan in Dec; expects product gross margins 75-80% in 2023.
STAR-T trial for DrugSorb-ATR: 1/3 of 120 patients enrolled; DSMB cleared; completion expected summer 2023; FDA submission planned.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytosorbents Corp reported preliminary unaudited full year 2022 results: revenue approximately $34.7 million.

Period: preliminary unaudited full year 2022
Revenue: approximately $34.7 million
Result: preliminary results

Exact text from the filing

Preliminary unaudited 2022 Total Revenue, which includes Product Sales and Grant Revenue, was approximately $34.7 million versus $43.2 million in 2021, and $24.9 million in pre-pandemic 2019

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytosorbents Corp reported preliminary unaudited fourth quarter 2022 results: revenue approximately $9.4 million.

Period: preliminary unaudited fourth quarter 2022
Revenue: approximately $9.4 million
Result: preliminary results

Exact text from the filing

Q4 2022 Total Revenue was approximately $9.4 million versus $10.8 million in Q4 2021, and versus $7.4 million in pre-pandemic Q4 2019

View on SEC.gov

Browse all earnings releases →

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-008819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.